z-logo
Premium
Association of lung adenocarcinoma clinical stage with gene expression pattern in noninvolved lung tissue
Author(s) -
Frullanti Elisa,
Colombo Francesca,
Falvella Felicia S.,
Galvan Antonella,
Noci Sara,
De Cecco Loris,
Incarbone Matteo,
Alloisio Marco,
Santambrogio Luigi,
Nosotti Mario,
Tosi Davide,
Pastorino Ugo,
Dragani Tommaso A.
Publication year - 2012
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.27426
Subject(s) - adenocarcinoma , lung cancer , biology , pathology , lung , stage (stratigraphy) , transcriptome , tumor suppressor gene , gene , cancer , gene expression , cancer research , medicine , carcinogenesis , genetics , paleontology
Associations between clinical outcome of cancer patients and the gene expression signature in primary tumors at time of diagnosis have been reported. To test whether gene expression patterns in noninvolved lung tissue might correlate with clinical stage in lung adenocarcinoma (ADCA) patients, we compared the transcriptome of noninvolved lung samples from 60 ADCA smoker patients of clinical stage I versus 60 patients with stage >I. Quantitative PCR of 10 genes with the most significant differential expression confirmed the statistical association with clinical stage in eight genes, six of which were downregulated in high‐stage patients. Five of these six genes were also downregulated in lung ADCA tissue as compared to noninvolved tissue. Studies in vitro indicated that four of the genes ( SLC14A1 , SMAD6 , TMEM100 and TXNIP ) inhibited colony formation of lung cancer cell lines transfected to overexpress the genes, suggesting their potential tumor‐suppressor activity. Our findings suggest that individual variations in the transcriptional profile of noninvolved lung tissue may reflect the lung ADCA patient's predisposition to tumor aggressiveness.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here